Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.

医学 内科学 危险系数 荟萃分析 肝细胞癌 肿瘤科 养生 子群分析 出版偏见 置信区间 相对风险 不利影响 随机对照试验
作者
Feng Xian,J Wu,Y-L Yuan,J Bie,G-H Xu
出处
期刊:PubMed 卷期号:27 (4): 1494-1502
标识
DOI:10.26355/eurrev_202302_31390
摘要

The triplet regimen based on the programmed cell death 1 (PD1)/ programmed cell death ligand 1 (PDL1) inhibitors combined radiotherapy and antiangiogenic drugs is a novel therapeutic strategy for hepatocellular carcinoma. We conducted a meta-analysis to evaluate the efficacy and safety of the triplet therapeutic regimen in the treatment of hepatocellular carcinoma.We searched scientific literature databases and clinical trial databases through October 31, 2022, for required studies. The pooled hazard ratio (HR) was used to analyze the overall survival (OS), progression-free survival (PFS), and the pooled relative risk (RR) was used to analyze the objective response rate (ORR), disease control rate (DCR), mortality rate (MR), and adverse events (AEs) through random or fixed effects model, 95% confidence interval (CI) was determined for all outcomes. Qualities of the included literature were assessed by MINORS Critical appraisal checklist. Funnel plot was used to assess publication bias in the included studies.Five studies (3 single-arm and 2 non-randomized comparative trials), including 358 cases, were enrolled. Meta-analysis showed that the pooled ORR, DCR, and MR were 51% (95% CI: 34%-68%), 86% (95% CI: 69-102%), and 38% (95% CI: 18-59%), respectively. Compared with triplet regimen, the single or dual-combination treatments had shorter OS (HR=0.53, 95%: 0.34-0.83 via univariate analysis; HR=0.49, 95%: 0.31-0.78 via multivariable analysis) and PFS (HR=0.52, 95%: 0.35-0.77 via univariate analysis; HR=0.54, 95%: 0.36-0.80 via multivariable analysis). Common AEs to triplet regimens included skin reaction (17%), nausea/vomiting (27%), fatigue (23%), while severe AEs (10%), fever (18%), diarrhea (15%), and hypertension (5%) without statistically significant differences.In the treatment of hepatocellular carcinoma, PD1/PDL1 inhibitors combined radiotherapy and antiangiogenic drugs achieved better survival benefits than alone or dual-combination regimens. In addition, the triple-combination therapy has tolerable safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LC发布了新的文献求助10
1秒前
zz发布了新的文献求助20
2秒前
清酒少年游完成签到,获得积分10
2秒前
彭于晏应助落寞的无施采纳,获得10
2秒前
4秒前
4秒前
搞怪的向珊关注了科研通微信公众号
4秒前
影默完成签到,获得积分10
7秒前
7秒前
悲凉的尔蓝完成签到,获得积分10
7秒前
7秒前
王星星发布了新的文献求助10
8秒前
8秒前
桐桐应助Sure采纳,获得30
10秒前
Geodada完成签到,获得积分10
11秒前
默认用户名完成签到,获得积分10
11秒前
完美世界应助Ashley采纳,获得10
11秒前
武雨寒发布了新的文献求助10
11秒前
高贵熊猫发布了新的文献求助10
12秒前
55555558完成签到,获得积分10
12秒前
安然完成签到,获得积分10
13秒前
13秒前
刘玥言发布了新的文献求助10
13秒前
柴胡发布了新的文献求助10
13秒前
风趣的老太应助Rita采纳,获得10
13秒前
无花果应助执着小熊猫采纳,获得10
14秒前
14秒前
白桦林泪发布了新的文献求助20
14秒前
HUAhua花发布了新的文献求助30
15秒前
16秒前
小倩给小倩的求助进行了留言
16秒前
研友_VZG7GZ应助彬彬采纳,获得10
18秒前
18秒前
18秒前
19秒前
Suraim完成签到,获得积分10
19秒前
小何发布了新的文献求助10
20秒前
jinjin125完成签到,获得积分20
20秒前
leihaha发布了新的文献求助10
21秒前
赘婿应助XY采纳,获得10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975871
求助须知:如何正确求助?哪些是违规求助? 3520207
关于积分的说明 11201502
捐赠科研通 3256611
什么是DOI,文献DOI怎么找? 1798403
邀请新用户注册赠送积分活动 877552
科研通“疑难数据库(出版商)”最低求助积分说明 806430